Thyroid Lobectomy for Papillary Thyroid Cancer: Long‐term Follow‐up Study of 1,088 Cases

Matsuzu, Kenichi; Sugino, Kiminori; Masudo, Katsuhiko; Nagahama, Mitsuji; Kitagawa, Wataru; Shibuya, H.; Ohkuwa, Keiko; Uruno, Takashi; Suzuki, Akifumi; Magoshi, Syunsuke; Akaishi, Junko; Masaki, Chie; Kawano, Michikazu; Suganuma, Nobuyasu; Rino, Yasushi; Masuda, Munetaka; Kameyama, Kaori; Takami, Hiroshi; Ito, Koichi

doi:10.1007/s00268-013-2224-1

Cited by 288 publications

(207 citation statements)

References 54 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Similar findings were reported by Memorial Sloan Kettering in a matched pair analysis [20]. Single institutions would provide increasingly compelling evidence that more aggressive therapy was not associated with improved outcome [21][22][23][24]. These findings were supported by updated national database studies, which also concluded that a more aggressive approach could not be supported in low-risk groups [25].…”

Section: Prace Poglądowesupporting

confidence: 72%

Wysoko zróżnicowany rak tarczycy — czy nie leczysz swoich pacjentów zbyt intensywnie?

Nixon

2016

Endokrynologia Polska

View full text Add to dashboard Cite

Over the last 50 years there has been a move towards more aggressive therapy for well-differentiated thyroid cancer. In recent times, however, international guidelines have shown some trend back towards a more conservative approach to treating low-risk patients. This review explores how the state of the art in well-differentiated thyroid cancer research has evolved in tandem with improvements in riskstratification. A focus on the surgical approach to the primary thyroid tumour and the regional lymphatics in addition to the interplay between surgical decision making and the use of radioactive iodine are presented to allow the reader to determine whether they are now overtreating patients with well-differentiated thyroid cancer. StreszczenieW ciągu ostatnich 50 lat nastąpiła zmiana w leczeniu wysoko zróżnicowanego raka tarczycy na rzecz bardziej agresywnej terapii. Jednakże, całkiem niedawno, międzynarodowe wytyczne wskazały trend w kierunku powrotu ku bardziej konserwatywnemu podejściu w leczeniu pacjentów niskiego ryzyka. W niniejszym artykule opisano jak najnowsze badania na temat wysoko zróżnicowanego raka tarczycy ewoluują równocześnie z ulepszeniami w stratyfikacji ryzyka. Podejście chirurgiczne do raka pierwotnego tarczycy oraz regionalnych węzłów chłonnych przedstawiono wraz ze wzajemnymi zależnościami operacyjnego procesu decyzyjnego i wykorzystaniem radiojodu, aby umożliwić czytelnikowi ustalenie, czy zbyt intensywnie leczy pacjentów z wysoko zróżnicowanym rakiem tarczycy.

show abstract

Section: Prace Poglądowesupporting

confidence: 72%

Wysoko zróżnicowany rak tarczycy — czy nie leczysz swoich pacjentów zbyt intensywnie?

Nixon

2016

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…How to include age as a prognostic factor in PTC is still a matter of debate, and previous studies have adopted various cutoffs as shown in Table 1 [3][4][5][6][7][8][9]. These studies' findings indicate that elderly patients are more likely to show recurrence and die of carcinoma compared to young patients.…”

Section: A) Patient Agementioning

confidence: 55%

“…Matsuzu et al also demonstrated that TS > 4 cm is one of the risk factors of carcinoma death [4]. Most studies set the cutoff at 3-4 cm according to the prognosis of patients (Table 2) [1,3,4,5,7,8,20].…”

Section: A) Patient Agementioning

confidence: 99%

Static and dynamic prognostic factors of papillary thyroid carcinoma [Review]

et al. 2014

View full text Add to dashboard Cite

Abstract. The two types of prognostic factors of papillary thyroid carcinoma (PTC) are static and dynamic. The following static prognostic factors have been conventionally adopted: age, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis based on pre-, intra-and post-operative findings. These factors are useful to decide therapeutic strategies for PTC patients, including the extent of surgery and radioactive iodine (RAI) ablation. However, even the combination of these factors evaluated pathologically postoperatively is not good enough at predicting recurrence in clinical settings. The dynamic prognostic factors of changes in serum thyroglobulin (Tg) and thyroglobulin antibody (TgAb) values in patients who have undergone a total thyroidectomy are important to evaluate the progression of carcinoma recurrence and to predict patients' cause-specific survival, regardless of their backgrounds and the clinicopathological features of their PTC. Dynamic prognostic factors are superior to static prognostic factors in terms of expressing the condition of recurrence on a real-time basis.Key words: Prognostic factors, Papillary thyroid carcinoma, Thyroglobulin, Thyroglobulin antibody, Lymph node metastasis PAPILLARY THYROID CARCINOMA (PTC) is the most common malignancy originating from the thyroid. Although it is generally indolent, several aggressive features of PTC predict a dire prognosis. The prognostic factors can be classified into two categories, i.e., static and dynamic prognostic factors. Static prognostic factors are based on the patient's background, findings of preoperative imaging studies, intraoperative gross findings, and postoperative pathological findings. They are useful for decisions regarding the choice of therapeutic strategies such as the extent of surgery, radioactive iodine (RAI) ablation and thyroid-stimulating hormone (TSH) suppression. In contrast, dynamic prognostic factors are based on changes over time in serum thyrogloblulin (Tg) and thyroglobulin antibody (TgAb) levels after total thyroidectomy. They are very important to estimate whether and how recurred lesions progress in real time and to predict the cause-specific survival (CSS) of PTC patients. In this review, the static and dynamic prognostic factors for PTC are reviewed separately. Static prognostic factorsStatic prognostic factors can be subdivided into three classifications based on the time of evaluation: pre-, intra-, and post-operation. The former two can be used to decide the extent of thyroidectomy and lymph node dissection.

show abstract

“…[27][28][29][30][31][32][33]. On the other hand, it has been reported that younger PTC patients have lower disease-free survival (DFS) than middle-aged patients.…”

Section: Categories Of Thyroid Malignanciesmentioning

confidence: 99%

“…AMES has marked tumor size more than 5 cm as high risk and UICC set two cut of at 2 and 4 cm [25,27]. Most of the recent studies have set the cut of at 3-4 cm according to prognosis of PTC patients [25,[27][28][29][30]35]. …”

Section: Papillary Thyroid Cancermentioning

confidence: 99%

Thyroid Cancers: Considerations, Classifications, and Managements

Khosravi¹,

Kouhi²,

Saeedi³

et al. 2017

Diagnosis and Management of Head and Neck Cancer

View full text Add to dashboard Cite

Rapidly increasing trend of thyroid cancer incidence has turned this disease into a global concern. An estimated number of 64,300 new cases of thyroid cancer occurred in men and women in 2016, which represents 3.8% of all new cancer cases of USA (htps://seer. cancer.gov/statfacts/html/thyro.html). Thus, there is a high possibility for every physician to encounter a case of thyroid cancer during his/her professional lifetime. In this chapter, we clariied epidemiology, diferent categories, and new approaches toward diagnosis and management of thyroid cancer.Keywords: thyroid cancer, epidemiology, diferentiated thyroid cancer, undiferentiated thyroid cancer, thyroid nodule Detailed epidemiology of thyroid cancerAs the most common endocrine cancer and ifth most common cancer in women, thyroid cancer includes approximately 1-1.5% of all new cases of cancer diagnosed annually in the USA based on previous data [1][2][3]. Thyroid cancer is more prevalent among women and those with positive family history of thyroid disease. Some prior studies have reported a worldwide increasing trend for thyroid cancer incidence in recent decades [4]. Annual percent change (APC) is a commonly used indicator for the assessment of changes in incidence. Based on US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, it has been reported 2.4% from 1980 to 1997 and 6.6% from 1997 to 2009 in both genders for thyroid cancer (data available at htp://seer.cancer.gov/statfacts/html/thyro.html).© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.According to [2009][2010][2011][2012][2013] data, the rate of new cases of thyroid cancer was 13.9 per 100,000 men and women per year (Figure 1). Table 1 summarizes number of new cases per 100,000 persons by race/ethnicity and sex. A recently published study on adolescent cancer incidence during 1975-2012 has reported a 2.12% increase for females and 1.59% for males between 15 and 19 years of age [5]. However, there is a study indicating that thyroid cancer incidence trend has slowed following release of American Thyroid Association (ATA) guideline in 2009 [6, 7]. It has been reported that overall thyroid cancer incidence had an increasing trend about 8% per year from 2000 to 2009. But APC showed a deceleration about 3% in men and 2.8% in women, which was conined to tumors less than 2.9 cm of size for women [7].Also, thyroid cancer-related mortality was estimated to consist 0.3% of all cancer-related deaths in 2016. A 5-year survival rate of 98.1% has been reported for thyroid cancer. Despite increasing trend of incidence, thyroid cancer mortality has a relatively stable rate about 0.5 cases per 100,000 persons both from 1973 to 2002 and 2009 to 2013 [8, 9].In conclusion, it seems that thyroid cancer has been following an ...

show abstract

Thyroid Lobectomy for Papillary Thyroid Cancer: Long‐term Follow‐up Study of 1,088 Cases

Cited by 288 publications

References 54 publications

Wysoko zróżnicowany rak tarczycy — czy nie leczysz swoich pacjentów zbyt intensywnie?

Wysoko zróżnicowany rak tarczycy — czy nie leczysz swoich pacjentów zbyt intensywnie?

Static and dynamic prognostic factors of papillary thyroid carcinoma [Review]

Thyroid Cancers: Considerations, Classifications, and Managements

Contact Info

Product

Resources

About